[go: up one dir, main page]

NO20063393L - Farmasoytiske preparater - Google Patents

Farmasoytiske preparater

Info

Publication number
NO20063393L
NO20063393L NO20063393A NO20063393A NO20063393L NO 20063393 L NO20063393 L NO 20063393L NO 20063393 A NO20063393 A NO 20063393A NO 20063393 A NO20063393 A NO 20063393A NO 20063393 L NO20063393 L NO 20063393L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparations
antagonists
disclosed
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
NO20063393A
Other languages
English (en)
Inventor
Mengwei Hu
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20063393L publication Critical patent/NO20063393L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmasøytiske preparater som omfatter NKl-antagonister beskrives.
NO20063393A 2003-12-22 2006-07-21 Farmasoytiske preparater NO20063393L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53173503P 2003-12-22 2003-12-22
PCT/US2004/042893 WO2005063243A1 (en) 2003-12-22 2004-12-20 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20063393L true NO20063393L (no) 2006-07-21

Family

ID=34738689

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063393A NO20063393L (no) 2003-12-22 2006-07-21 Farmasoytiske preparater

Country Status (16)

Country Link
US (1) US20050153999A1 (no)
EP (1) EP1706116A1 (no)
JP (1) JP2007515425A (no)
KR (1) KR20060113737A (no)
CN (1) CN1897942A (no)
AR (1) AR046769A1 (no)
AU (1) AU2004308935A1 (no)
BR (1) BRPI0417950A (no)
CA (1) CA2550432A1 (no)
MX (1) MXPA06007210A (no)
NO (1) NO20063393L (no)
PE (1) PE20051049A1 (no)
PL (1) PL380482A1 (no)
TW (1) TW200531686A (no)
WO (1) WO2005063243A1 (no)
ZA (1) ZA200605080B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120545A1 (es) * 2006-04-05 2012-05-21 Opko Health Inc Composicion farmaceutica que comprende la forma i cristalina de la sal clorhidrato monohidrato de (5s,8s)-8-[{(1r)-1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4,5]decan-2-ona
NZ571693A (en) * 2006-04-05 2011-12-22 Opko Health Inc Pharmaceutical formulations: salts of 8-[{ 1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy} -methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
WO2007114922A2 (en) * 2006-04-05 2007-10-11 Schering Corporation Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
AR066191A1 (es) * 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
PE20081891A1 (es) * 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
NZ592823A (en) * 2008-11-23 2012-12-21 Pfizer Spirocyclic lactams for treating neurodegenerative and/or neurological disorders
AU2014271269B2 (en) * 2009-08-14 2016-11-03 Opko Health, Inc. Intravenous formulations of neurokinin-1 antagonists
CN105503870A (zh) * 2009-08-14 2016-04-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
CN112472814A (zh) * 2012-01-23 2021-03-12 萨奇治疗股份有限公司 神经活性类固醇制剂和治疗中枢神经系统障碍的方法
NL2018041B1 (en) * 2016-12-22 2018-06-28 Land Life Company B V Process to prepare a biodegradable pulp product
JP2022533971A (ja) * 2019-05-15 2022-07-27 ベクソン バイオメディカル，インク． 皮下注射のためのケタミン製剤
EP3991730A4 (en) 2019-06-28 2023-08-09 Shanghai Shengdi Pharmaceutical Co., Ltd NEUROKININ-1 ANTAGONIST
WO2021198255A1 (en) 2020-04-03 2021-10-07 Nerre Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
CA3177477A1 (en) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
JP2023551145A (ja) 2020-11-18 2023-12-07 ベクソン バイオメディカル，インク． 医薬化合物の錯化剤塩製剤
KR20230127252A (ko) * 2020-12-25 2023-08-31 상하이 쉥디 파마슈티컬 컴퍼니 리미티드 5-ht3 수용체 길항제와 조합된 nk1 길항제 전구약물화합물의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2791346B3 (fr) * 1999-03-25 2001-04-27 Sanofi Sa Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
AU2002254309B2 (en) * 2001-03-20 2006-02-02 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
PE20030762A1 (es) * 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1

Also Published As

Publication number Publication date
CA2550432A1 (en) 2005-07-14
CN1897942A (zh) 2007-01-17
PL380482A1 (pl) 2007-02-05
US20050153999A1 (en) 2005-07-14
KR20060113737A (ko) 2006-11-02
MXPA06007210A (es) 2006-08-18
AR046769A1 (es) 2005-12-21
TW200531686A (en) 2005-10-01
WO2005063243A1 (en) 2005-07-14
EP1706116A1 (en) 2006-10-04
BRPI0417950A (pt) 2007-04-17
JP2007515425A (ja) 2007-06-14
AU2004308935A1 (en) 2005-07-14
PE20051049A1 (es) 2006-01-03
ZA200605080B (en) 2008-06-25

Similar Documents

Publication Publication Date Title
NO20052739D0 (no) CCR5-antagonister som medikamenter
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
HRP20080564T3 (hr) Dihidrotetrabenazini i farmaceutski pripravci koji ih sadrže
NO20052306D0 (no) Dispergerbare farmasoytiske blandinger.
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
DK1592457T3 (da) Folat-vinblastin-konjugat som lægemiddel
CY1108547T1 (el) Αναλογα σωματοστατινης
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
LTC1608344I2 (lt) Per burną vartojamos kladribino kompozicijos
NO20063393L (no) Farmasoytiske preparater
SE0301653D0 (sv) Novel compounds
PL375874A1 (pl) Wodne kompozycje farmaceutyczne 2,6-diizopropylofenolu
IS7051A (is) Lyfjasamsetningar
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
DE60316954D1 (de) Shampoozusammensetzungen
NO20044092L (no) Oftalmisk sammensetning som innbefatter ascomycin
DK1648882T3 (da) 3-fluor-piperidiner som NMDA/NR2B-antagonister
BRPI0417205A (pt) composições farmacêuticas
NO995945L (no) Nye forbindelser
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
NO20044164L (no) Farmasoytiske sammensetninger

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application